Anonymous (2026). Cost-Effectiveness of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation: Insights from CASTLE-HTx.. Heart rhythm.
Anonymous. Cost-Effectiveness of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation: Insights from CASTLE-HTx.. Heart rhythm. 2026; PMID: 42162774
Anonymous. Cost-Effectiveness of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation: Insights from CASTLE-HTx.[J]. Heart rhythm. 2026.
@article{paper2026,
author = {Anonymous},
title = {Cost-Effectiveness of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation: Insights from CASTLE-HTx.},
journal = {Heart rhythm},
year = {2026},
note = {PMID: 42162774},
}
TY - JOUR AU - Anonymous TI - Cost-Effectiveness of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation: Insights from CASTLE-HTx. T2 - Heart rhythm PY - 2026 AN - PMID:42162774 ER -
The CASTLE-HTx trial (NCT04649801) showed that the combination of catheter ablation and guideline-directed medical therapy (GDMT) was associated with a lower likelihood of a composite of death from any cause, implantation of a left ventricular assist device (LVAD), or heart transplantation (HTx) in patients with end-stage heart failure (HF) and atrial fibrillation (AF).